Major depressive disorder: new clinical, neurobiological, and treatment perspectives.
Major depressive disorder: new clinical, neurobiological, and treatment perspectives.
复制标题
DOI：
10.1016/s0140-6736(11)60602-8
复制
发表时间：
2012-03-17
期刊：
影响因子：
168.9
通讯作者：
Phillips, Mary L.
中科院分区：
文献类型：
--
作者：
Kupfer, David J.;Frank, Ellen;Phillips, Mary L.
在本次研讨会中，我们讨论了过去5年在诊断、神经生物学和治疗方面的进展。在诊断方面，精神疾病和医学共病被强调为改善对抑郁症的适当评估和管理的重要因素。神经生物学方面的进展也有所增加，我们的目标是指出与这种疾病的评估和治疗选择相关的遗传、分子和神经成像研究。此外，还讨论了针对抑郁症的心理治疗的进一步研究、抗抑郁药物的持续应用、新治疗化合物的开发以及新的躯体治疗的现状。我们解决了两个与治疗相关的问题：选择性5-羟色胺再摄取抑制剂的自杀风险，以及妊娠期间抗抑郁药的安全性。虽然已经取得了明显的进展，但还没有完全令人满意的治疗重度抑郁症的方法可用。
In this Seminar we discuss developments from the past 5 years in the diagnosis, neurobiology, and treatment of major depressive disorder. For diagnosis, psychiatric and medical comorbidity have been emphasised as important factors in improving the appropriate assessment and management of depression. Advances in neurobiology have also increased, and we aim to indicate genetic, molecular, and neuroimaging studies that are relevant for assessment and treatment selection of this disorder. Further studies of depression-specific psychotherapies, the continued application of antidepressants, the development of new treatment compounds, and the status of new somatic treatments are also discussed. We address two treatment-related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety of antidepressants in pregnancy. Although clear advances have been made, no fully satisfactory treatments for major depression are available.